# Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

> **NCT02275533** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 82 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Biopsy
- **OTHER:** Clinical Observation
- **PROCEDURE:** Echocardiography Test
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT02275533
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-07-02
- **Primary completion:** 2025-07-28
- **Final completion:** 2026-10-08
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02275533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02275533, "Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02275533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*